Heart failure or heart success?

Cardiovasc Res. 2021 Feb 22;117(3):e29-e34. doi: 10.1093/cvr/cvab022.
No abstract available

Keywords: Cardiac myosin; Ferric carboxymaltose; Sotagliflozin; HFrEF.

MeSH terms

  • Cardiovascular Agents / adverse effects
  • Cardiovascular Agents / therapeutic use*
  • Evidence-Based Medicine
  • Ferric Compounds / therapeutic use
  • Glycosides / therapeutic use
  • Heart Failure, Systolic / diagnosis
  • Heart Failure, Systolic / drug therapy*
  • Heart Failure, Systolic / mortality
  • Heart Failure, Systolic / physiopathology
  • Hospitalization
  • Humans
  • Maltose / analogs & derivatives
  • Maltose / therapeutic use
  • Randomized Controlled Trials as Topic
  • Recovery of Function
  • Research Design
  • Sodium-Glucose Transporter 1 / antagonists & inhibitors
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
  • Stroke Volume / drug effects*
  • Treatment Outcome
  • Urea / analogs & derivatives
  • Urea / therapeutic use
  • Ventricular Function, Left / drug effects*

Substances

  • Cardiovascular Agents
  • Ferric Compounds
  • Glycosides
  • SLC5A1 protein, human
  • Sodium-Glucose Transporter 1
  • Sodium-Glucose Transporter 2 Inhibitors
  • omecamtiv mecarbil
  • ferric carboxymaltose
  • Maltose
  • (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
  • Urea